晚期肝细胞癌靶向治疗及个性化治疗的现状.pdfVIP

传染病信息 2019 年 4 月 30 日 第 32 卷 第 2 期 Infect Dis Info, Vol. 32, No. 2, April 30, 2019 ·103· 晚期肝细胞癌靶向治疗及个性化治疗的现状 刘　淦，孙　杰，张　婷，卢姗姗，向　姣，陆荫英，白文林 　　[ 摘要 ]　随着精准医疗理念的普及，在晚期肝细胞癌系统性治疗领域，新技术驱动的个性化治疗逐渐流行，晚期肝细 胞癌靶向治疗也迎来了新的发展契机。本文就晚期肝细胞癌靶向治疗的现状与过去、新技术驱动的个性化治疗的发展与未来 进行综述，着重介绍以 sorafenib 为代表的分子靶向药的发展历程，以及二代测序、人源肿瘤组织异种移植模型等新技术在 个性化精准治疗中的应用。 　　 　　[ 关键词 ]　肝细胞肝癌；分子靶向治疗；个性化治疗；精准医学 　　[ 中国图书资料分类号 ]　R735.7　　　　[ 文献标志码 ] A　　　　[ 文章编号 ]　1007-8134(2019)02-0103-07 　　DOI: 10.3969/j.issn.1007-8134.2019.02.002 Current status of targeted therapy and individualized therapy for advanced hepatocelluar carcinoma * * LIU Gan, SUN Jie, ZHANG Ting, LU Shan-shan, XIANG Jiao, LU Yin-ying , BAI Wen-lin Comprehensive Liver Cancer Diagnosis and Treatment Center, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China Department of Pathology, 960 Military Hospital of Chinese PLA, Jinan 250000, China *Corresponding author. LU Yin-ying, E-mail: luyinying1973@163.com; BAI Wen-lin, E-mail: wz_liugan@163.com 　　[Abstract]　With the popularization of precision medicine, new technology-driven individualized therapy has become increasingly popular, molecular targeted therapy has been faced with a novel development opportunity for treatment of advanced hepatocellular carcinoma. This article reviews the past and current status of targeted therapy for advanced hepatocellular carcinoma, and the future development of individualized therapy driven by new technologies. Emphasis is focused on the progress of molecular targeted drugs represented by sorafenib, as well as the application of new technologies such as second-generation sequencing and patient-derived tumor xenograft models in individualized precision therapy. 　　　　 　　[Ke